Ec 3.1.3.1 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
46 | Malignant rheumatoid arthritis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2008-007346-63-GB (EUCTR) | 05/04/2011 | 11/10/2010 | Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase (bIAP), An Inflammation modulating moiety, in RA patients - REUMAP | Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase (bIAP), An Inflammation modulating moiety, in RA patients - REUMAP | Rheumatoid Arthritis | Product Name: bIAP Product Code: EC 3.1.3.1 INN or Proposed INN: bovine intesastinal alkaline phosphatase (bIAP) Other descriptive name: bIAP | Alloksys Life Sciences B.V. | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | United Kingdom |